GIST CANCER RESEARCH FUND NEEDS YOU!
July 12, 2017
Gastrointestinal Stromal Tumor or GIST is a rare, orphan cancer which starts in a type of tissue called the stromal or the body’s connective tissue (fat, muscle, blood vessels, deep skin tissues, nerves, bones or cartilage). GIST is a silent cancer often spreading before the patient has symptoms. Each year, approximately 5,000 adults in the United States alone are diagnosed with GIST Cancer.
The GIST Cancer Research Fund has committed itself to support the GIST Cancer Team of Doctors, Researchers and Nurses who have dedicated their lives to the treatment and cure of this deadly cancer. Their affiliations with the following hospitals and cancer research centers make it possible to treat and change many GIST patients’ lives.
• Brigham Woman Hospital/Dana Farber Cancer Institution,
• Fox Chase Cancer Center, Philadelphia, PA
• Memorial-Sloan Kettering Cancer Center, New York, NY
• Oregon Health Sciences University Cancer Institute,
• University of Pittsburgh Cancer Center, Pittsburgh, PA
Revolutionary research has led to the discovery of a common mutation (KIT CD117) that is found in GIST patients. This mutation separates GIST from the other cancers that can affect the GI tract. This breakthrough has given oncologists valuable data required to help GIST patients fight this deadly disease.The GIST Cancer Medical Team are very familiar with GIST patients’ unique needs, treatment options, managing side effects and monitoring considerations. We are very proud to be part of this heroic team of medical warriors who make this fight against GIST Cancer a personal goal.